12:04 PM EST, 01/28/2025 (MT Newswires) -- Humacyte ( HUMA ) and closely held Pluristyx expanded their partnership to include gene editing to support Humacyte's ( HUMA ) development of its investigational BioVascular Pancreas using cell lines provided by Pluristyx.

Humacyte's ( HUMA ) BVP is designed to treat insulin-dependent diabetes.

The expanded partnership builds on Humacyte's ( HUMA ) existing license of Pluristyx's PluriBank cell lines, the companies said Tuesday in a statement.

Price: 4.50, Change: -0.01, Percent Change: -0.22